CD19 and non-Hodgkin lymphoma: The potential superiority of CD19 3G has been suggested in a clinical trial, in which CD19 2G CAR-T-cells (CD28) and CD19 3G CAR-T-cells (CD28 and 4-1BB) were infused simultaneously in 16 patients with relapsed or refractory non-Hodgkin’s lymphoma.